Abstract
Scleroderma is a rare systemic autoimmune disease with multiple organ manifestations, including skin fibrosis. The groups of disorders classified as scleroderma mimics share the common thread of skin thickening but are otherwise quite incongruous in terms of underlying disease process and other organ involvement. This article reviews the clinical presentation, etiology, and treatment options available for scleroderma mimics, including morphea, scleredema, diabetic cheiroarthropathy, scleromyxedema, nephrogenic systemic fibrosis, and eosinophilic fasciitis. Through greater understanding of these diseases and the associated extradermal implications, we hope to facilitate recognition of scleroderma and its mimics.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
• Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64(2):217–28. This is an excellent review of the spectrum of morphea and localized scleroderma.
Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2005.
• Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64(2):231–42. This is an important summary on the direction in which outcome measures and treatment of localized scleroderma are moving.
• Wortsman X, Gutierrez M, Saavedra T, Honeyman J. The role of ultrasound in rheumatic skin and nail lesions: a multi-specialist approach. Clin Rheumatol 2011; 30(6):739–48. This is a discussion of the use of ultrasound in evaluation of scleroderma skin.
Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160(5):1075–82.
• Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63(7):1998–2006. This is an excellent example of how a randomized controlled trial can be carried out in this rare disease.
Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–7.
Kreuter A, Hyun J, Skrygan M, Sommer A, Tomi NS, Breuckmann F, et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res. 2006;298(6):265–72.
Kreuter A, Hyun J, Skrygan M, Sommer A, Bastian A, Altmeyer P, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. 2006;155(3):600–7.
Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355–9.
Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, et al. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol. 2006;25(1):3–15.
Meguerditchian C, Jacquet P, Beliard S, Benderitter T, Valero R, Carsuzza F, et al. Scleredema adultorum of Buschke: an under recognized skin complication of diabetes. Diabetes Metab. 2006;32(5 Pt 1):481–4.
Ikeda Y, Suehiro T, Abe T, Yoshida T, Shinoki T, Tahara K, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Intern Med. 1998;37(10):861–4.
Thumpimukvatana N, Wongpraparut C, Lim HW. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol. 2010;37(12):1036–9.
Alsaeedi SH, Lee P. Treatment of scleredema diabeticorum with tamoxifen. J Rheumatol. 2010;37(12):2636–7.
Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complications. 1989;3(2):77–87.
Rosenbloom AL. Diabetic thick skin and stiff joints. Diabetologia. 1989;32(1):74–6.
Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10–20.
Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42(1):31–5.
Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273–81.
Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37–43.
Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006;107(2):463–6.
Laimer M, Namberger K, Massone C, Koller J, Emberger M, Pleyer L, et al. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema. Acta Derm Venereol. 2009;89(6):631–5.
Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1.
• Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol 2010; 2(11):427–33. This is an important summary of the relationship of gadolinium to NSF.
Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250(2):371–7.
Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis—a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61(5):868–74.
Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am. 2009;47(5):833–40. vi.
Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol. 2008;144(11):1527–9.
Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543–8.
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. 2011;26(3):1099–101.
Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1975;88:70–86.
Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after—what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93–101.
Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47(1):29–35.
Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol. 1995;22(3):563–5.
Baumann F, Bruhlmann P, Andreisek G, Michel BA, Marincek B, Weishaupt D. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol. 2005;184(1):169–74.
Barnes L, Rodnan GP, Medsger TA. Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol. 1979;96(2):493–518.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nashel, J., Steen, V. Scleroderma Mimics. Curr Rheumatol Rep 14, 39–46 (2012). https://doi.org/10.1007/s11926-011-0220-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-011-0220-8